ATLANTA, Georgia, United States, April 7, 2026
Artivion, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the NEXUS® Aortic Arch System, a next-generation branched endovascular stent graft designed for the minimally invasive treatment of complex aortic arch disease, including chronic aortic dissections. This milestone represents a significant advancement in cardiovascular MedTech innovation and regulatory-driven clinical solutions.
FDA Approval Backed by Strong Clinical Trial Outcomes
The FDA approval is supported by data from the NEXUS TRIOMPHE IDE clinical trial, which demonstrated highly favorable patient outcomes in a high-risk population. The study reported 90% survival from lesion-related death, 90% freedom from disabling stroke, and an impressive 98% freedom from reintervention due to endoleaks at one year post-treatment, highlighting the device’s strong safety and efficacy profile.
These results are particularly significant given that patients with aortic arch disease have historically had limited treatment options, often requiring invasive open-chest surgery associated with higher risks, longer recovery times, and increased healthcare burden. The NEXUS system introduces a minimally invasive alternative, potentially transforming clinical practice in vascular surgery and interventional cardiology.
Innovative Technology Targets Unmet Clinical Needs
Advertisement
The NEXUS Aortic Arch System, developed by Endospan Ltd., is a branched endovascular stent graft platform designed to address the anatomical complexities of the aortic arch. Unlike traditional approaches, this system enables precise placement and effective repair of aortic lesions, reducing procedural risk while improving patient outcomes and recovery timelines.
This innovation is particularly important for patients diagnosed with aneurysms and dissections in the aortic arch, a population that has remained underserved due to the technical challenges of treating this region using conventional methods. The ability to deliver a minimally invasive solution with strong clinical validation represents a major step forward in advanced medical device development.
Additionally, Artivion’s partnership with Endospan underscores the importance of collaborative innovation in MedTech, combining engineering expertise, clinical research, and regulatory strategy to bring life-saving technologies to market.
Strategic Growth and Future Commercial Opportunities
Following FDA approval, Artivion has the option to acquire Endospan within 90 days, supported by a $150 million financing facility, positioning the company for strategic expansion in the cardiovascular device market.
The approval not only strengthens Artivion’s portfolio of aortic stent grafts and cardiovascular solutions, but also enhances its ability to address complex surgical challenges with innovative, less invasive technologies. The company’s global presence, spanning over 100 countries, further supports the rapid adoption and commercialization of the NEXUS system.
As healthcare systems increasingly prioritize minimally invasive procedures, technologies like NEXUS are expected to play a critical role in improving patient outcomes while reducing healthcare costs and hospital stays.
The FDA approval of the NEXUS® Aortic Arch System marks a major milestone in cardiovascular MedTech innovation, offering a clinically validated, minimally invasive solution for complex aortic diseases. With strong clinical data, regulatory endorsement, and strategic growth potential, Artivion is well-positioned to lead advancements in endovascular therapy and patient-centered care. This development underscores the critical role of regulatory approval, clinical validation, and advanced device engineering in shaping the future of modern healthcare solutions.
Source: Artivion press release
